Data Sheet (Cat.No.T5987)

TargetMol

Potassium oxonate

Chemical Properties



CAS No. : 2207-75-2

Formula: C4H2KN3O4

Molecular Weight: 195.17

Storage: Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Potassium oxonate is a uricase inhibitor that suppresses the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate and is commonly used to establish hyperuricemia models.
Targets(IC50)	Others
In vivo	Potassium oxonate is a component of S-1, a mixture containing a prodrug of the antitumor agent 5-fluorouracil, that suppresses the gastrointestinal toxicity of 5-FU without inhibiting its antitumor activity in rats[1].Formulations containing Potassium oxonate have been used to treat gastric, pancreatic, lung, head, neck, and breast carcinomas[2].

Solubility Information

Solubility	H2O: 9.09 mg/mL (46.57 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.1237 mL	25.6187 mL	51.2374 mL
5 mM	1.0247 mL	5.1237 mL	10.2475 mL
10 mM	0.5124 mL	2.5619 mL	5.1237 mL
50 mM	0.1025 mL	0.5124 mL	1.0247 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yoshisue K, Masuda H, Matsushima E,et al.Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J].Drug Metab Dispos. 2000 Oct;28(10):1162-7.

Zhuang Z, Liu A, Zhang J, et al.Hyperuricemia suppresses lumican, exacerbating adverse remodeling after myocardial infarction by promoting fibroblast phenotype transition.Journal of Translational Medicine.2024, 22(1): 1-17.

Chhetri P . Current Development of, Anti-Cancer Drug S-1[J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481